Elicio Therapeutics Inc (ELTX)
$4.18
+0.12
(+2.83%)▲
Performance
- $4.10$4.33$4.18
1.91%
Downside
Day's Volatility :5.31%
Upside
3.46%
- $2.96$11.45$4.18
29.19%
Downside
52 Weeks Volatility :74.15%
Upside
63.49%
Returns
| Period | Elicio Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -47.56% | 0.0% |
6 Months | -16.3% | 0.0% |
1 Year | -46.07% | 0.0% |
3 Years | -60.85% | -20.8% |
Highlights
Market Capitalization | 47.0M |
Book Value | - $0.16 |
Earnings Per Share (EPS) | 0.92 |
PE Ratio | 4.74 |
Wall Street Target Price | 10.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -96.8% |
Return On Equity TTM | -353.02% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -41.0M |
Diluted Eps TTM | 0.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.38 |
EPS Estimate Next Year | -3.03 |
EPS Estimate Current Quarter | -0.96 |
EPS Estimate Next Quarter | -0.79 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 139.23%
Technicals Summary
Sell
Neutral
Buy
Elicio Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Elicio Therapeutics Inc | -2.9% | -16.3% | -46.07% | -60.85% | -75.41% |
 Regeneron Pharmaceuticals, Inc. | -1.87% | 19.58% | 40.07% | 76.89% | 303.42% |
 Novo Nordisk A/s | -0.41% | 3.5% | 43.88% | 170.56% | 453.76% |
 Alnylam Pharmaceuticals, Inc. | 0.98% | 77.71% | 43.4% | 41.49% | 212.93% |
 Vertex Pharmaceuticals Incorporated | 2.83% | 19.05% | 39.11% | 157.0% | 173.37% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Elicio Therapeutics Inc | 4.74 | 4.74 | NA | -3.38 | -3.53 | -0.97 | NA | -0.16 |
Regeneron Pharmaceuticals, Inc. | 30.86 | 30.86 | 1.59 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 46.01 | 46.01 | 2.08 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Elicio Therapeutics Inc | Buy | $47.0M | -75.41% | 4.74 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $128.4B | 303.42% | 30.86 | 32.04% |
Novo Nordisk A/s | Buy | $600.4B | 453.76% | 46.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.1B | 212.93% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.3B | 173.37% | 32.84 | -4.74% |
Insights on Elicio Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 43.9% return, outperforming this stock by 90.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 170.6% return, outperforming this stock by 231.5%
Company Information
elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell
Organization | Elicio Therapeutics Inc |
Employees | 32 |
CEO | Mr. Robert T. Connelly |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$4.18
+2.83%
Keyarch Acquisition Corp
$4.18
+2.83%
Connexa Sports Technologies Inc
$4.18
+2.83%
Us Value Etf
$4.18
+2.83%
First Wave Biopharma Inc
$4.18
+2.83%
Global X Msci Next Emerging
$4.18
+2.83%
Fat Projects Acquisition Corp
$4.18
+2.83%
Capital Link Global Fintech
$4.18
+2.83%
Applied Uv Inc
$4.18
+2.83%